BackAdaptimmune Therapeutics Plc Overview

Adaptimmune Therapeutics Plc Receivables

Track Adaptimmune Therapeutics Plc's receivables ($29M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$28.89M
↑ 21.59% YoYΔ $5.13M vs prior year quarter

Peer average

Loading

Adaptimmune Therapeutics Plc Receivables History

Loading

Adaptimmune Therapeutics Plc vs. peers: Receivables Comparison

Loading

Adaptimmune Therapeutics Plc Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Adaptimmune Therapeutics Plc (ADAP) FAQ

Adaptimmune Therapeutics Plc (ADAP) currently reports a receivables of $29M as of June 2025. That compares with $24M in the prior-year period — up 21.6% year over year. Use the charts on this page to explore Adaptimmune Therapeutics Plc's receivables history and peer comparisons.

Adaptimmune Therapeutics Plc's receivables increased from $24M to $29M — a 21.6% year-over-year increase (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adaptimmune Therapeutics Plc reported $29M in receivables as of June 2025. That compares with $24M in the prior-year period — up 21.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $29M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adaptimmune Therapeutics Plc, and consider following ADAP for alerts when major investors trade the stock.

Adaptimmune Therapeutics Plc is classified in the Healthcare sector. On receivables, it currently shows $29M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADAP with unrelated industries.